Here are the DEF 14A proxy statements from Drugs Made In America Acquisition Corp. Rights (DMAAR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DMAAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAAR filings page.
Drugs Made In America Acquisition Corp. filed Amendment No. 1 to its definitive proxy statement to update voting thresholds and share counts tied to an Extraordinary General Meeting. The amendment states 33,517,143 Ordinary Shares outstanding as of the Record Date and elsewhere lists 33,717,143 Ordinary Shares as of the Record Date. It specifies that, assuming all Ordinary Shares are present, the Company will need 11,827,619 and alternatively 11,760,953 Public Shares to approve the Extension Proposal, and 6,241,429 and alternatively 6,141,429 Public Shares to approve the Adjournment Proposal. The Amendment replaces Article 48.7 and is dated April 16, 2026.
Drugs Made in America Acquisition Corp. is asking shareholders to approve changes that would give it up to 12 extra months, from April 29, 2026 to April 29, 2027, to complete a business combination.
Each one-month extension would require the sponsor to loan the lesser of $300,000 or $0.04 per non‑redeemed public share into the trust account. Public shareholders can redeem shares for about $10.52 per share, based on roughly $242 million held in the trust as of the record date, regardless of how they vote. If the extension is not approved and no deal closes by the current deadline, the SPAC will redeem all public shares and wind up.